Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data

Dinutuximab beta is approved for the maintenance treatment of patients with high-risk neuroblastoma (HR-NB), including patients with relapsed/refractory (R/R) disease. However, the data on its use in real-world clinical practice is limited. We retrospectively reviewed the clinical records of 54 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wieczorek, Aleksandra, Żebrowska, Urszula, Ussowicz, Marek, Sokół, Agnieszka, Stypińska, Marzena, Dembowska-Bagińska, Bożenna, Pawińska-Wąsikowska, Katarzyna, Balwierz, Walentyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455178/
https://www.ncbi.nlm.nih.gov/pubmed/37629294
http://dx.doi.org/10.3390/jcm12165252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455178/
https://www.ncbi.nlm.nih.gov/pubmed/37629294
http://dx.doi.org/10.3390/jcm12165252

Ejemplares similares